To evaluate the potential of different myeloid cell subsets from pSS patients to activate NK cells, we investigated expression of ligands for activating NK receptor NKG2D such as MICa/b and ULBP1 or for inhibitory receptors such as PCNA on cDC2, cDC1, and in Mo from these individuals and in HD (Fig 2C and Appendix Fig S4A–C). Here, KLRK1 is linked to Huntington disease.